Current Issue

A Global Quest for Reducing Harm in Patient Care
David B. Nash, MD, MBA
February 2019 Vol 12, No 1 - Editorial
Read More
Comparing the Medicaid Prospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies in 2015 and 2016
Sergio I. Prada, MPA, PhD, Johan S. Loaiza, BS
February 2019 Vol 12, No 1 - Regulatory
Read More
Implementation of a Pharmacist-Led Diabetes Management Protocol
Lana T. Al-Omar, PharmD, BCPS, Sarah L. Anderson, PharmD, FCCP, BCPS, BCACP, Amber D. Cizmic, PharmD, BCACP, Tara B. Vlasimsky, PharmD, BCPS, BCACP
February 2019 Vol 12, No 1 - Clinical, Original Research
Stakeholder Perspective
Collaborative Efforts Help the Avoidance of Diabetes Mismanagement
by Jack E. Fincham, PhD, RPh
Read More
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
Diana Brixner, RPh, PhD, Gary Oderda, PharmD, MPH, Joseph Biskupiak, PhD, MBA, Douglas S. Burgoyne, PharmD, FAMCP, Steven G. Avey, RPh, MS, FAMCP, Steven R. Feldman, MD, PhD
February 2019 Vol 12, No 1 - Business, Case Study, Online First
Read More
US Healthcare Trends and Contradictions in 2019
F. Randy Vogenberg, PhD
February 2019 Vol 12, No 1 - Industry Trends
Read More
Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis
Arijita Deb, PhD, Nilanjana Dwibedi, PhD, Traci LeMasters, PhD, Jo Ann Hornsby, MD, Wenhui Wei, PhD, Usha Sambamoorthi, PhD
February 2019 Vol 12, No 1 - Clinical, Original Research
Stakeholder Perspective
Comorbidities in Rheumatoid Arthritis Present Clinical, Economic Challenges for All Stakeholders
by Gary Branning, MBA
Read More
A Shift in Party Majority, a Shift in Priority? What the Pharmaceutical Industry Can Expect
Gary Branning, MBA, Randy Ross, BA, Kathryn Hayes, BA
February 2019 Vol 12, No 1 - Industry Trends
Read More

Conference Correspondent

Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections
Conference Correspondent - IDWeek 2018
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
Conference Correspondent - IDWeek 2018
Health-Related Social Vulnerabilities in a Pediatric Outpatient Antimicrobial Therapy Program
Conference Correspondent - IDWeek 2018

Most Popular Articles

Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
Kenneth LaPensee, PhD, MPH, Thomas Lodise, PharmD, PhD
December 2018 Vol 11, No 9 - Business, Original Research
Pharmacist-Led Drug Therapy Problem Management in an Interprofessional Geriatric Care Continuum: A Subset of the PIVOTS Group
Ashley M. Campbell, PharmD, Kim C. Coley, PharmD, Jason M. Corbo, PharmD, Teresa M. DeLellis, PharmD, Matthew Joseph, PharmD, Carolyn T. Thorpe, PhD, MPH, Melissa S. McGivney, PharmD, Patricia Klatt, PharmD, Lora Cox-Vance, MD, Vincent Balestrino, MD, Heather Sakely, PharmD
December 2018 Vol 11, No 9 - Clinical, Original Research
Emerging Therapeutic Approaches to Treatment-Resistant Depression: Meeting Unmet Clinical Needs
Supplements - MOA Magnifier

Online First

The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
Diana Brixner, RPh, PhD, Gary Oderda, PharmD, MPH, Joseph Biskupiak, PhD, MBA, Douglas S. Burgoyne, PharmD, FAMCP, Steven G. Avey, RPh, MS, FAMCP, Steven R. Feldman, MD, PhD
Cost-effectiveness studies of pharmaceutical agents that will soon be released to the market are an important tool that payers and health plans can use when making decisions on coverage, formulary positioning, and budgets.
Read More

Select Drug Updates

Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals
FDA Approvals in 2017 Represent a 21-Year High
FDA Approvals of Brand-Name Prescription Drugs in 2017
Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma
View All Updates

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME